Emtricitabine, rilpivirine, and tenofovir alafenamide (Oral)
Medically reviewed by Drugs.com. Last updated on Apr 12, 2022.
Emtricitabine/rilpivirine/tenofovir alafenamide is not approved for the treatment of chronic hepatitis B virus (HBV) infection and the safety and efficacy of emtricitabine/rilpivirine/tenofovir alafenamide have not been established in patients coinfected with human immunodeficiency virus-1 (HIV-1) and HBV. Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with emtricitabine/rilpivirine/tenofovir alafenamide. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several moths in patients who are coinfected with HIV-1 and HBV and discontinue emtricitabine/rilpivirine/tenofovir alafenamide. If appropriate, initiation of antihepatitis B therapy may be warranted .
Commonly used brand name(s)
In the U.S.
- Odefsey
Available Dosage Forms:
- Tablet
Therapeutic Class: Antiretroviral Agent
Pharmacologic Class: Nucleoside Reverse Transcriptase Inhibitor
Uses for emtricitabine, rilpivirine, and tenofovir alafenamide
Emtricitabine, rilpivirine, and tenofovir alafenamide combination is used to treat human immunodeficiency virus (HIV) infection. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). Emtricitabine, rilpivirine, and tenofovir alafenamide is usually given to patients who have not received any HIV treatment in the past or to replace their current antiviral medicines provided that they meet certain requirements.
Emtricitabine, rilpivirine, and tenofovir alafenamide will not cure HIV infection or AIDS. It works by lowering the amount of HIV in the blood and it will also help your immune system. This may help delay some of the medical conditions that usually result from AIDS or HIV disease. It will not keep you from spreading HIV to other people.
Emtricitabine, rilpivirine, and tenofovir alafenamide is available only with your doctor's prescription.
Before using emtricitabine, rilpivirine, and tenofovir alafenamide
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For emtricitabine, rilpivirine, and tenofovir alafenamide, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to emtricitabine, rilpivirine, and tenofovir alafenamide or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of emtricitabine, rilpivirine, and tenofovir alafenamide combination in children younger than 12 years of age weighing less than 35 kilograms (kg). Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of e..
